Paris, 19 MayPress releaseGTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent, and is also granted new patent on recombinant antithrombin pro

First Page		Document Content
Date: 2012-08-14 05:05:18 ATryn Anticoagulants Genetic engineering Goats Medicine Clinical research Biopharmaceutical Monoclonal antibodies Antithrombin Biotechnology Biology Pharmacology		Paris, 19 MayPress releaseGTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent, and is also granted new patent on recombinant antithrombin pro Add to Reading List Source URL: www.lfb.fr Download Document from Source Website File Size: 34,51 KB Share Document on Facebook

	Biomolecular Interaction and The Interactome.doc DocID: 1pQMx - View Document
	Domestic Sales Outsourcing Agreement for Recombinant Human Antithrombin Preparation Signed Tokyo, Japan, July 30, The Japan Blood Products Organization (head office: Tokyo, Japan, President and representative di DocID: 1lLMs - View Document
	Paris, 19 MayPress releaseGTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent, and is also granted new patent on recombinant antithrombin pro DocID: 1aPBm - View Document
	Routine Coagulation Reagents Activated Partial Thromboplastin Time (aPTT) Antithrombin III (ATIII) Prothrombin Time (PT) Thrombin Time (TT) Fibrinogen DocID: 1aOgJ - View Document
	HAEMATOLOGIC TECHNOLOGIES INCResearch Reagents Catalog DocID: 1apfC - View Document